ICMR Current Affairs - 2019
Category Wise PDF Compilations available at This Link
The Union Ministry of Health and Family Welfare (MoHFW) and Indian Council of Medical Research (ICMR) had launched India Hypertension Management Initiative (IHMI).
The IHMI aims to reduce disability and death related to cardiovascular disease (CVD), the leading cause of death in India. It also aims to strengthen CVD component of Health Ministry’s National Program for Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS).
India Hypertension Management Initiative (IHMI)
The IHMI is collaborative project of ICMR, MoHFW, World Health Organization (WHO), State Governments and Resolve to Save Lives initiative of Vital Strategies. Its primary goal is to reduce morbidity and mortality due to CVDs, by improving control of high blood pressure, which is leading risk factor for CVDs among adults in India.
The IHMI focuses on five essential components of scalable treatment of hypertension. It will also focus on strengthening hypertension management and monitoring at primary health care level, within existing healthcare system. It is aligned with WHO’s Global HEARTS Initiative and National Guidelines.
It will support adoption of standardized simplified treatment plans for managing high blood pressure, ensure regular and uninterrupted supply of quality-assured medications, and patient-centred services that reduce barriers to treatment adherence.
It will also focus on data on hypertension to improve it through streamlined monitoring systems and lessons learned and practice-based evidence that will inform further interventions to improve cardiovascular care. IHMI will be progressively rolled out in 25 districts in first two years across districts selected by MoHFW for expansion of active screening and intensification of treatment activities for hypertension.
The Indian Council of Medical Research (ICMR) and Ministry of Health inked Memorandum of Understanding (MoU) with the International Vaccine Institute (IVI) to collaborate on vaccine research and development.
The signing of the MoU is a continuation of India’s partnership with IVI to provide safe, effective and affordable vaccines for people around the world. With this partnership, India is committing an annual contribution of US $5,00,000 to IVI.
India is a vaccine industry powerhouse that supplies 60% of the world’s vaccines. India has with a long history of scientific collaboration with IVI. IVI has been partnering with Indian vaccine manufacturers, research institutes, government, and public health agencies on vaccine R&D. One of the most successful collaboration of IVI was with India’s Shantha Biotech on development of Shanchol, world’s first low-cost oral cholera vaccine. The vaccine was licensed in India in 2009 and WHO-prequalified in 2011.
International Vaccine Institute (IVI)
IVI is Seoul (South Korea) based international nonprofit organization devoted to developing and introducing new and improved vaccines to protect the people, especially children, against deadly infectious diseases. It was established in 1997 on the initiatives of the United Nations Development Programme (UNDP).
Its work is exclusively on vaccine development and introduction specifically for people in developing countries, with a focus on neglected diseases affecting these regions. Currently, IVI has 40 countries and the World Health Organization (WHO) as signatories to its Establishment Agreement. India officially became a signatory to the IVI in 2012.
Indian Council of Medical Research (ICMR)
The ICMR is India’s apex scientific body for the formulation, coordination and promotion of biomedical research. It was established in 1911 as Indian Research Fund Association (IRFA) making it one of the oldest and largest medical research bodies in the world. The ICMR functions under the Department of Health Research, Union Ministry of Health and Family Welfare.